Treatment Persistence and Medication Switch Associated With Subsequent Fractures After Osteoporotic Fractures
Authors' conclusion
Patients with non-persistent AOM had higher risk of subsequent fractures than persistent users when allowing AOM switch. Switching AOM potency may influence the risk of subsequent vertebral fractures and warrants further investigation.
Study context
- Population
- Patients with osteoporotic fractures who initiated anti-osteoporosis medication (AOM) between 2013 and 2016, Taiwan
- Participants
- 119,473 patients
- Exposure
- Non-persistent vs persistent anti-osteoporosis medication (AOM), allowing AOM switch
- Outcome
- Subsequent fractures ≥3 months after initiating AOM
Methodological detailsTaiwan National Health Insurance claims data, multivariate Cox models
- Taiwan National Health Insurance claims data
- Multivariate Cox models
Main finding
As reported in the abstract
Subsequent fractures
Estimate (95% CI)
Non-persistent AOMvs Persistent AOM
aHR (hip fracture) 1.31(1.21–1.42)
Non-persistent AOMvs Persistent AOM
aHR (vertebral fracture) 1.17(1.13–1.22)
Non-persistent AOMvs Persistent AOM
aHR (radius fracture) 1.16(1.08–1.25)
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| Subsequent vertebral fractures: persistent AOM with high- to low-potency switchvs persistent AOM without potency switchHigh-potency: zoledronate and denosumab | 1.28 (1.02–1.60) | |
| 0.512Adjusted hazard ratio (log scale) |
Treatment patterns
- Switched from index AOM
- 26.8%
- Persistent with AOM within 1 year
- 52%
- Follow-up, mean (SD), months
- 46.4 (15.6)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Treatment Persistence and Medication Switch Associated With Subsequent Fractures After Osteoporotic Fractures. J Clin Endocrinol Metab. Published 1 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →